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Background: Ulcerative colitis is a chronic inflammatory disease and involves multiple etiological factors. Acetic
acid (AA)-induced colitis is a reproducible and simple model, sharing many characteristics with human colitis.
N-acetylcysteine (NAC) has been widely used as an antioxidant in vivo and in vitro. NAC can affect several signaling
pathways involving in apoptosis, angiogenesis, cell growth and arrest, redox-regulated gene expression, and
inflammatory response. Therefore, NAC may not only protect against the direct injurious effects of oxidants, but
also beneficially alter inflammatory events in colitis. This study was conducted to investigate whether NAC could
alleviate the AA-induced colitis in a porcine model.
Methods: Weaned piglets were used to investigate the effects of NAC on AA-induced colitis. Severity of colitis was
evaluated by colon histomorphology measurements, histopathology scores, tissue myeloperoxidase activity, as well as
concentrations of malondialdehyde and pro-inflammatory mediators in the plasma and colon.
The protective role of NAC was assessed by measurements of antioxidant status, growth modulator, cell apoptosis, and
tight junction proteins. Abundances of caspase-3 and claudin-1 proteins in colonic mucosae were determined by the
Western blot method. Epidermal growth factor receptor, amphiregulin, tumor necrosis factor-alpha (TNF-α), and toll-like
receptor 4 (TLR4) mRNA levels in colonic mucosae were quantified using the real-time fluorescent quantitative PCR.
Results: Compared with the control group, AA treatment increased (P < 0.05) the histopathology scores, intraepithelial
lymphocyte (IEL) numbers and density in the colon, myeloperoxidase activity, the concentrations of malondialdehyde
and pro-inflammatory mediators in the plasma and colon, while reducing (P < 0.05) goblet cell numbers and the
protein/DNA ratio in the colonic mucosa. These adverse effects of AA were partially ameliorated (P < 0.05) by dietary
supplementation with NAC. In addition, NAC prevented the AA-induced increase in caspase-3 protein, while
stimulating claudin-1 protein expression in the colonic mucosa. Moreover, NAC enhanced mRNA levels for epidermal
growth factor and amphiregulin in the colonic mucosa.
Conclusion: Dietary supplementation with NAC can alleviate AA-induced colitis in a porcine model through regulating
anti-oxidative responses, cell apoptosis, and EGF gene expression.
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N-acetylcysteine (NAC), the precursor of L-cysteine and
therefore reduced glutathione, has been widely used as
an antioxidant in vivo and in vitro [1]. NAC is rapidly
metabolized by the small intestine to produce glutathi-
one [2] and is usually not detectable in the plasma or* Correspondence: houyq@aliyun.com
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reproduction in any medium, provided the ortissues of pigs receiving no NAC supplementation [3].
Previous studies have shown the protective effect of
NAC against the toxicity of chemicals due to its dual
role as a nucleophile and as a -SH donor [4]. Specifically,
NAC acts as a direct ROS scavenger to regulate the
redox status and also affects several signaling pathways
involved in apoptosis, angiogenesis, cell growth and ar-
rest, redox-regulated gene expression, and inflammatory
response [5,6]. Moreover, NAC exerts an indirect anti-
oxidant effect through the synthesis of glutathione, atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Therefore, NAC may not only protect against the direct
injurious effects of oxidants, but also beneficially alter
inflammatory events [8].
Inflammatory bowel diseases (IBD), including Crohn’s
disease (CD) and ulcerative colitis (UC), are complex
disorders characterized by chronic, local, and systemic
inflammation as well as a spontaneously relapsing course
[9]. Ulcerative colitis is a chronic inflammatory disease
[10] and involves multiple etiological factors [11,12]. A
large body of evidence suggests that oxidant derivatives
and reactive oxygen species (ROS) are produced in ex-
cess by the inflamed mucosa and may be pathogenic fac-
tors in IBD [13,14]. Oxidative stress have an important
bearing on inflammation via the activation of redox-
sensitive transcriptional factors such as nuclear factor kB
(NF-kB) and activator protein 1, which regulate expres-
sion of key genes encoding pro-inflammatory mediators
and protective antioxidant proteins. In support of this
view, pharmacological agents that lower the amounts of
reactive oxygen metabolites may reduce inflammation
[13]. Many animal models of IBD have been developed
to study its pathogenesis and therapeutic means [15].
Acetic acid (AA)-induced colitis is a reproducible and
simple model, sharing many characteristics with human
colitis [11,16].
In the intestinal tract, energy status is a fundamental
regulator of epithelial cell metabolism [3]. An energy
deficit has been considered to be a pathogenic factor in
ulcerative colitis, which is substantiated by the fact that
the intestinal mucosa has a limited capacity for de novo
synthesis of purine nucleotides [17] and is more prone
to reduced ATP concentrations compared with the liver
or muscle [18]. On the other hand, IL-6 and tumor ne-
crosis factor α (TNF-α) has been shown to play an im-
portant role in the pathogenesis of inflammatory bowel
disease [19]. These pro-inflammatory cytokines drive the
activation and recruitment of inflammatory cells, amplify
the production of other pro-inflammatory cytokines, and
activate nuclear transcription factors, thereby promoting
and maintaining the inflammatory response [20]. Add-
itionally, release of transforming growth factor-α (TGF-
α) and expression of TGF-α mRNA are increased after
acute gastric injury and in the colonic mucosa from pa-
tients with IBD [21,22].
Neonates are prone to various stresses, such as early-
weaning, inflammatory bowel disease, and infection,
resulting in intestinal mucosal injury and absorptive dys-
function [23-25]. However, effective prevention and
treatments are currently limited [26]. Many nutrients
(vitamin E, selenium and trimetazidine) have been inves-
tigated as possible agents to protect animals against the
IBD. Dietary supplementation with vitamin E and selen-
ium reduced both the severity of colonic lesions and thelevels of malondialdehyde (MDA) [27,28]. Likewise, in-
traperitoneal administration of trimetazidine improved
macroscopic and microscopic scores and decreased co-
lonic myeloperoxidase (MPO) activity in rats receiving
administration of AA [29]. In previous studies, we have
reported that NAC reduced inflammation, alleviated oxi-
dative stress, improved energy status, and ameliorate tis-
sue damage in the small intestine of piglets [2,30]. Thus,
we postulated that dietary supplementation with NAC
may alleviate the AA-induced colonic injury in piglets.
The purpose of the present study was to test this hy-
pothesis and to elucidate the underlying molecular
mechanisms. As the piglet is a well-established animal
model for studying human gastrointestinal disease, find-
ings of this study will provide vital clues for prevention
of human colitis.
Methods
Animal care and diets
The animal use protocol for this research was approved
by the Animal Care and Use Committee of Hubei Prov-
ince. Eighteen healthy crossbred female piglets (Duroc ×
Landrace × Yorkshire), which were reared by sows, were
weaned at 21 days of age. After a 7-day period of adapta-
tion, piglets (average body weight of 6.44 ± 0.39 kg) were
housed individually in stainless steel metabolic cages
(1.20 × 1.10 m2) and maintained in an environmentally
controlled room (25°C) by air conditioning, with electric
light being provided between 8:00 AM and 8:00 PM
[26]. Each cage was equipped with a feeder and a nipple
waterer to allow piglets free access to food and drinking
water [26,31-33]. The corn- and soybean meal-based diet
was formulated to meet National Research Council
(NRC 1998) requirements for all nutrients [2].
Experimental design
In the first week, all weanling piglets had free access to
the basal diet to help them adapt to solid food. Then,
eighteen healthy piglets were allocated randomly into
one of the three treatments: 1) control group (piglets fed
the basal diet and receiving intrarectal administration of
10 mL of sterile saline); 2) AA group (piglets fed the
basal diet and receiving intrarectal administration of 10
mL of 10% AA); 3) NAC group (piglets fed the basal diet
supplemented with 500 mg/kg NAC and receiving
intrarectal administration of 10 mL of 10% AA). NAC
(powder) was well mixed with the basal diet. Diets for
the control and AA groups were supplemented with 500
mg/kg cornstarch to obtain approximately isocaloric di-
ets. The dosage of NAC was chosen according to the re-
sults of our previous study indicating that dietary
supplementation with 500 mg/kg NAC could ameliorate
growth depression and restore intestinal function in
weanling piglets [2,30]. It is unnecessary to use non-
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cause the dietary supplementation with 500 mg/kg NAC
only resulted in an increase of 0.0042% nitrogen. On day
15 of the trial, piglets in the AA and NAC groups re-
ceived intrarectal administration of 10 mL of 10% AA,
whereas the control group piglets received the same vol-
ume of saline. The dosage of AA was chosen according
to the studies of Jurjus et al. [15]. During days 0–15 of
the trial (pre-challenge), all the piglets had free access to
feed and drinking water. To exclude a possible effect of
AA-induced reduction in food intake on the piglet intes-
tine, the control and NAC piglets were pair-fed the same
amount of feed per kg body weight as AA piglets during
days 15–21 of the trial (post-challenge with AA). On day
22 of the trial, all piglets were sacrificed by injection of
sodium pentobarbital (50 mg/kg BW) to obtain the co-
lonic mucosa for the evaluation of intestinal morphology
and biochemical analysis [34].
Blood sample collection
On day 22 of the trial, blood samples were collected
from the anterior vena cava into heparinized vacuum
tubes (Becton Dickinson Vacutainer System, Franklin
Lake, NJ, USA), as we previously described [26]. Blood
samples were centrifuged at 3,000 rpm for 10 min at 4°C
to obtain plasma [26,35]. Plasma was stored at −80°C
until analysis.
Intestinal sample collection
The piglet abdomen was surgically opened immedi-
ately from the sternum to the pubis, and then the
whole gastrointestinal tract was immediately exposed
[26,36]. The large intestine, dissected free of the mes-
entery, was placed on a chilled stainless steel tray.
Colon segments (5- to 10-cm) were obtained, flushed
gently with ice-cold phosphate buffered saline (PBS,
pH 7.4), and placed in 10% fresh chilled formalin solu-
tion for histological measurements [26,34]. Additional
colon segments were opened longitudinally and the
contents were flushed with ice-cold PBS [26,37].
Thereafter, the mucosa was collected by scraping using
a sterile glass microscope slide at 4°C [26,38], rapidly
frozen in liquid nitrogen, and stored at −80°C until
analysis. All samples were collected within 15 min
after sacrifice.
Histologic assessments of colonic damage
Tissue samples for the morphometric study were
dehydrated and embedded in paraffin, sectioned at 4
μm, and stained with hematoxylin and eosin [26].
Stained sections were determined for evidence of co-
lonic injury using the following criteria: crypt lesion,
bowel wall thickening, lymphocyte infiltration, goblet
cell depletion, and denuded epithelium [9,39,40]. Thedegree of damage on microscopic cross-sections of the
colon was graded semi-quantitatively using a score of
0 to 20. For example, grades of crypt lesion from 0 to 4
were as follows: 0: intact crypt, 1: loss of the one-third
tissue, 2: loss of the two-third tissue, 3: loss of the en-
tire crypt, 4: erosion [41]. The total possible score was
20 (absence of any abnormality = 0 and most severe in-
jury = 20) [13]. Morphometric measurements were
performed with a light microscope (American Optical
Co., Scientific Instrument Div., Buffalo, NY, USA).
Crypt depth (the distance from the crypt mouth to
the base) was measured using a linear ocular micro-
meter with a computer-assisted morphometric system
(BioScan Optimetric, BioScan Inc., Edmonds, WA,
USA). Colonic intraepithelial lymphocyte (IEL) num-
ber and goblet cell number in crypts were measured.
The variables were expressed per 100 enterocytes.
Measurements were taken in 10 well-oriented crypts
from each intestinal section of a study animal. On the
basis of the cellular morphology, differences among
the nuclei of enterocytes, goblet cells, and lympho-
cytes were clearly distinguishable at 400× magnifica-
tion. Intra-villus lamina propria cell density was
determined by counting total visibly stained nuclei
and total lymphocytes in 8 fields from each section
using a grid ocular (Olympus, Microplanet). Cell dens-
ity was expressed as the number of total stained cells
or the number of lymphocytes per 1,000 μm2 [34]. The
number of lymphocytes in relation to the number of
total cells was also calculated. All morphometric ana-
lysis was done by the same person, who was blinded to
the treatments.
Measurement of mucosal DNA, RNA, and protein
DNA, RNA, and protein were extracted from the colonic
mucosa, using TRI REAGENT-RNA/DNA/Protein isola-
tion reagent and their concentrations were determined
colorimetrically, as previously described [26]. Mucosal
DNA was analyzed fluorimetrically using the method of
Prasad et al. [42]. RNA was determined by spectropho-
tometry using a modified Schmidt-Tannhauser method
as described by Munro and Fleck [43]. Protein was ana-
lyzed according to the method of Lowry et al. [44]. For
measurement of colonic DNA and RNA levels, the
mucosa was homogenized (~2 min) in a 100-fold volume
of ice-cold saline (0.9%) and the homogenate was
centrifuged at 1,800 × g for 10 min at 4°C to obtain the
supernatant fluid for analysis. For measurement of mu-
cosal protein, intestinal mucosal samples (~0.1 g) were
homogenized using a tissue homogenizer in 1 mL of ice-
cold PBS-EDTA buffer (0.05 mol/L Na3PO4, 2.0 mol/L
NaCl, 2 mmol/L EDTA, pH 7.4) and the homogenates
were centrifuged at 12,000 × g for 10 min at 4°C to ob-
tain the supernatant fluid for assays.
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The colonic mucosa (~200 mg), homogenized in a nine-
fold volume of freezing saline, was centrifuged at 2,500
rpm for 10 min at 4°C to obtain the supernatant fluid
used for assays. Myeloperoxidase, superoxide dismutase
(SOD), catalase (CAT), and malondialdehyde (MDA) in
the plasma and colonic mucosa were determined using
commercially available kits (Nanjing Jiancheng Bioengin-
eering Institute, Nanjing, China).
Determination of proinflammatory cytokines in the
plasma and colonic mucosae
Frozen intestinal mucosal samples were powdered under
liquid nitrogen, then homogenized in ice-cold 0.9% NaCl
solution using a homogenizer (1 g sample/9 mL of 0.9%
NaCl). The homogenates were centrifuged at 3,000 rpm
for 15 min at 4°C to obtain the supernatant fluid [32].
Tumor necrosis factor-α (TNF-α) in plasma was analyzed
using commercially available 125I RIA kits (Beijing North
Institute of Biological Technology, Beijing, China). The de-
tection limit was 0.3 ng/mL and the intra-and inter-assay
coefficients of variation were 5% and 8%, respectively.
Interleukin-6 (IL-6) and prostaglandin E2 (PGE2)
in plasma and the supernatant fluid of colonic mucosae
were analyzed using commercially available 125I RIA
kits (Beijing Sino-UK institute of Biological Tech-
nology, Beijing, China). The detection limits for
interleukin-6 and prostaglandin E2 analyses were 50
and 0.12 pg/mL, respectively. The coefficients of vari-
ation for intra-and inter-assays of interleukin-6 were < 7%
and < 15%, respectively. The coefficients of variation for
intra-and inter-assays of prostaglandin E2 were < 7.5%
and < 10.5%, respectively.
Determination of EGF in plasma and TGF-α in
colonic mucosae
Epidermal growth factor (EGF) in plasma and transforming
growth factor-α (TGF-α) in colonic mucosae were analyzed
using commercially available 125I RIA kit (Beijing Sino-UK
Institute of Biological Technology, Beijing, China). The
coefficients of variation for intra-and inter-assay of EGF
were < 5% and < 10%, respectively. The coefficients of vari-
ation for intra-and inter-assay of TGF-α were 4.4% and
7.4%, respectively. The detection limit for EGF and TGF-α
were 0.1 ng/mL and < 5 pg/mL, respectively.
Protein immunoblot analysis
Analysis of caspase-3 and claudin-1 proteins in colonic
mucosae were performed by western blot as described
by Hou et al. [26]. Briefly, frozen samples were pow-
dered under liquid nitrogen and homogenized in lysis
buffer. The homogenates were centrifuged at 12,000 × g
for 15 min at 4°C to get the supernatant fluid. A portion
of this fluid is mixed with 2 × SDS sample buffer in a 1:1ratio. The samples were boiled for 5 min and cooled on
ice before western blot analysis. The proteins (60 μg/
sample for caspase-3, claudin-1 and β-actin) were sepa-
rated by electrophoresis on a 10% (for caspase-3) or 12%
(for claudin-1) polyacrylamide gel. Proteins were electro-
phoretically transferred to a polyvinylidene difluoride
(PVDF) membrane. Non-fat dry milk in TBS-T (1 ×
Tris-buffered saline including 0.1% Tween 20) was used
to block membranes for at least 1 h at room tem-
perature [26]. Membranes were then incubated with pri-
mary antibodies overnight at 4°C: caspase-3 (rabbit
polyclonal antibodies from Cell Signaling Technology,
Inc., Danvers, MA, USA; dilution 1:1000), claudin-1
(rabbit monoclonal antibodies from Invitrogen Technol-
ogy, Inc., Danvers, MA, USA; dilution 1:1000), β-actin
(mouse monoclonal antibody from Sigma Chemicals; di-
lution 1:5000). The membranes were washed three times
for 10 min with TBS-T and incubated for 1 h at room
temperature with anti-rabbit (mouse) immunoglobulin
G horseradish peroxidase-conjugated secondary anti-
body (Beijing ZhongShan Golden Bridge Biological
Technology Co., LTD, China; dilution 1:10000) [31]. In-
cubation of the secondary antibodies was followed by
five washes for 8 min. Blots were developed using an En-
hanced Chemiluminescence western blotting kit (ECL-
plus, Amersham Biosciences, Sweden), visualized and
quantified using an imaging system (Alpha Innotech
FluorChem FC2, CA, USA) [2,30].
Determination of EGFR, AR, TNF-α and TLR4 mRNA
levels using quantitative real-time polymerase-chain
reaction (RT-PCR)
Epidermal growth factor receptor (EGFR), Amphi-
regulin (AR), tumor necrosis factor-alpha (TNF-α)
and toll-like receptor 4 (TLR4) mRNA levels in
colonic mucosae were quantified using quantitative
RT-PCR as described by Hou et al. [30]. Appro-
ximately 100 mg of a frozen mucosal sample, pow-
dered under liquid nitrogen using a mortar and pestle,
were homogenized in a buffer and total RNA was iso-
lated using the TRIzol Reagent protocol (Invitrogen,
Carlsbad, CA, USA). Total RNA was quantified using
the NanoDrop® ND-2000 UV–VIS spectrophotometer
(Thermo Scientific, Wilmington, DE, USA) at an OD
of 260 nm, and the purity was assessed by determining
the OD260/OD280 ratio. All of the samples had an
OD260/OD280 ratio above 1.8 corresponding to 90-
100% pure nucleic acids. Meanwhile, the integrity of
RNA in each sample was assessed using 1% denatured
agarose gel electrophoresis. RNA was used for quan-
titative RT-PCR analysis when the sample had a 28 S/
18 S rRNA ratio ≥ 1.8 [30].
Total RNA was reverse transcribed using the Prime-
Script® RT reagent kit with gDNA Eraser (Takara,
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tion. cDNA was synthesized and stored at −20°C until
use. The RT-PCR analysis of gene expression was
performed using primers for EGFR, AR, TNF-α, TLR4,
and ribosomal protein L4 (RPL4) (Table 1), and the
SYBR® Premix Ex Taq™ (Takara, Dalian, China) on an
Applied Biosystems 7500 Real-Time PCR System (Foster
City, CA, USA). The total volume of PCR reaction system
was 50 μL. In brief, the reaction mixture contained 0.2 μM
of each primer, 25 μL of SYBR® Premix Ex Taq™ (2×) and 4
μL of cDNA in a 50-μL reaction volume. All PCRs were
done in triplicate on a 96-well RT-PCR plate under the fol-
lowing conditions (two-step amplification): 95°C for 30 sec,
followed by 40 cycles of 95°C for 3 sec and 60°C for 30 sec.
A subsequent melting curve (95°C for 15 sec, 60°C for 1
min and 95°C for 15 sec) with continuous fluorescence
measurement and final cooling to room temperature was
processed. Amplification products were verified by melting
curves and agarose gel electrophoresis. Results were ana-
lyzed by the cycle threshold (CT) method [45]. Each bio-
logical sample was run in triplicate, RPL4 was used to
standardize the relative expression of all genes investigated.
Statistical analysis
Data, expressed as means ± SD, were analyzed by one-way
analysis of variance. The normality and constant variance
for experimental data were tested by the Levene’s test. If
data did not have homogenous variance, they underwent
logarithm transformation to meet the necessary assump-
tions of analysis of variance [46]. Differences among treat-
ment means were determined by Duncan’s multiple range
tests. All statistical analyses were performed using SPSS
17.0 software (Chicago, IL, USA). P values < 0.05 were
taken to indicate statistical significance [45].Table 1 Primers for RT-PCR analysis
Gene Primers
EGFR
Forward 5′- GGCCTCCATGCTTTTGAGAA -3′
Reverse 5′- GACGCTATGTCCAGGCCAA -3′
AR
Forward 5′-GAGTACGATAACGAACCGCACA -3′
Reverse 5′-TTTCCACTTTTGCCTCCCTTT -3′
TNF-α
Forward 5′- TCCAATGGCAGAGTGGGTATG -3′
Reverse 5′- AGCTGGTTGTCTTTCAGCTTCAC -3′
TLR4
Forward 5′- GCCTTTCTCTCCTGCCTGAG -3′
Reverse 5′- AGCTCCATGCATTGGTAACTAATG -3′
RPL4
Forward 5′- GAGAAACCGTCGCCGAAT -3′
Reverse 5′- GCCCACCAGGAGCAAGTT -3′
The oligonucleotide primers were designed from pig gene sequences in the
GenBank NM-2140075 (for EGFR), NM-214376 (for AR), NM-214022.1 (for TNF-α),
AB188301 (for TLR4), and DQ845176 (for RPL4). To avoid amplification of
potentially contaminating genomic DNA, the primers were designed to span
introns and intron-exon boundaries.Results
Growth performance
Average daily feed intake, average daily weight gain, and
F/G (feed:gain) of the piglets between days 15 and 21 of
the trial did not differ among the three groups (Table 2).
Intestinal morphometry
Colonic morphometric measurements are summarized in
Table 3. The score for the AA group was significantly
higher than the control and NAC group piglets (P < 0.05).
AA administration caused a reduction (P < 0.05) in goblet
cells/100 enterocytes and an increase (P < 0.05) in IEL/100
enterocytes and lymphocytic density. NAC supplementa-
tion increased (P < 0.05) goblet cells/100 enterocytes, de-
creased (P < 0.05) IEL/100 enterocytes and lymphocytic
density, in comparison with the AA group.
Concentrations of DNA, RNA and protein in the
colonic mucosa
Compared with the control group, AA treatment re-
duced protein/DNA ratio (P < 0.05) in the colonic mu-
cosa (Table 4). Dietary NAC supplementation prevented
such an effect of AA in piglets (P < 0.05). (Table 4).
Effects of NAC on redox status
Data on the redox status in plasma and colonic mucosa
are illustrated in Table 5. Compared with the control, pig-
lets in the AA group exhibited increases (P < 0.05) in the
activities of MPO, the concentrations of MDA in the
plasma and colon, as well as decreases (P < 0.05) in the ac-
tivities of CAT in the colonic mucosa. In comparison with
the AA piglets, NAC supplementation decreased
(P < 0.05) the activities of MPO, and the concentrations of
MDA in the plasma and colon.
Concentrations of inflammatory mediators in plasma
and colonic mucosae, EGF in plasma and TGF-α in the
colonic mucosa
Data on the concentrations of inflammatory mediators
in plasma and colonic mucosae are shown in Table 6.
Compared to the control, AA administration resulted in
an increase (P < 0.05) in concentrations of TNF-α inTable 2 Effects of NAC supplementation on the growth
performance of AA-treated piglets (between days 15 and
21 of the trial)
Items Control AA NAC
Average daily feed intake (g/day) 575 ± 3 576 ± 2 572 ± 4
Average daily weight gain (g/day) 301 ± 48 266 ± 69 267 ± 41
F/G (feed: gain) 1.9 ± 0.3 2.3 ± 0.7 2.2 ± 0.3
Data are means ± SD, n = 6. Control = piglets fed the basal diet and received
intrarectal administration of sterile saline; AA = piglets fed the basal diet and
received intrarectal administration of acetic acid; NAC = piglets fed the basal
diet supplemented with 500 mg/kg NAC and received intrarectal
administration of acetic acid.
Table 3 Effects of NAC supplementation on the colonic
mucosal morphology of AA-treated piglets
Items Control AA NAC
Score 6.3 ± 1.5a 12.5 ± 2.6b 8.3 ± 1.8a
Crypt Depth1, μm 190 ± 2.2 200 ± 3.5 231 ±3.8
Goblet cells/100 enterocytes 10.3 ± 2.2b 7.4 ±0.7a 9.8 ±1.6b
IEL2/100 enterocytes 1.6 ± 0.5a 2.7 ± 0.8b 1.8 ± 0.9a
Cell density3 1.3 ± 0.4 0.9 ± 0.3 1.0 ± 0.1
Lymphocytic density3 1.6 ± 0.2a 2.4 ± 0.7b 1.7 ± 0.3a
Data are means ± SD, n = 6. Control = piglets fed the basal diet and received
intrarectal administration of sterile saline; AA = piglets fed the basal diet and
received intrarectal administration of acetic acid; NAC = piglets fed the basal
diet supplemented with 500 mg/kg NAC and received intrarectal
administration of acetic acid. a-b: Values within a row with different letters
differ (P < 0.05). 1Crypt depth: The distance from the crypt mouth to the base.
The same crypt columns were used to determine the number of IEL, goblet
cells expressed per 100 enterocytes. 2IEL = Intraepithelial lymphocytes.
3 Intravillus lamina propria cell and lymphocytic density expressed as number
of total cells or number of lymphocytes per 1,000 μm2.
Table 5 Effects of NAC on redox status in the plasma and
colonic mucosa of AA-induced piglets
Items Control AA NAC
Plasma
MPO, U/ L 136 ± 12a 172 ± 24b 150 ± 24a
SOD, U/ mL 87.3 ± 30.2 82.0 ± 13.6 77.2 ± 11.8
CAT, U/ mL 4.58 ± 1.29 3.64 ± 1.03 6.50 ± 3.19
MDA, nmol/ mg protein 5.12 ± 0.51a 6.97 ± 1.24b 5.41 ± 1.02a
Colonic mucosa
MPO, U/g wet mucosa 0.071 ± 0.003a 0.095 ± 0.018b 0.063 ± 0.016a
SOD, U/mg protein 20.9 ± 1.4 18.5 ± 4.2 20.5 ± 6.0
CAT, U/mg protein 1.16 ± 0.12b 0.99 ± 0.17a 0.87 ± 0.16a
MDA, nmol/mg protein 0.33 ± 0.04a 0.58 ± 0.16b 0.41 ± 0.15a
Data are means ± SD, n = 6. Control = piglets fed the basal diet and received
intrarectal administration of sterile saline; AA = piglets fed the basal diet and
received intrarectal administration of acetic acid; NAC = piglets fed the basal diet
supplemented with 500 mg/kg NAC and received intrarectal administration of
acetic acid. a-b: Values within a row with different letters differ (P < 0.05).
MPO Myeloperoxidase, SOD superoxide dismutase, CAT catalase, MDA
malondialdehyde.
Table 6 Effects of NAC on proinflammatory mediators
and growth modulator in the plasma and colonic mucosa
Item Control AA NAC
Plasma
TNF-α, ng/mL 0.61 ± 0.17a 0.84 ± 0.11b 0.49 ± 0.14a
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treatment with NAC, the concentrations of TNF-α
(P < 0.05) in plasma and of TGF-α (P < 0.05) in the co-
lonic mucosa were decreased. Moreover, concentrations
of EGF in the plasma of the NAC-supplemented piglets
were increased (P < 0.05), compared with the AA group.
Abundance of caspase-3 and claudin-1 proteins in the
colon mucosa
Caspase-3 and claudin-1 proteins were determined in the
piglet colon (Figures 1 and 2). Compared with the control,
AA administration caused an increase (P < 0.05) in the
abundance of the caspase-3 protein and a decrease
(P < 0.05) in the claudin-1 protein in the colonic mucosa.
In contrast, NAC reduced (P < 0.05) the abundance of the
caspase-3 protein and enhanced (P < 0.05) the abundance
of the claudin-1 protein in the colonic mucosa.
EGFR, AR, TNF-α and TLR4 mRNA levels in the
colonic mucosa
Gene expression of EGFR, AR, TNF-α and TLR4 were
measured in the colon mucosa by real-time PCR (Table 7).
NAC supplementation markedly increased the abundanceTable 4 Effects of NAC supplementation on the colonic
growth of AA-induced piglets
Items Control AA NAC
DNA, mg/g 2.93 ± 0.19 3.20 ± 0.44 2.64 ± 0.38
RNA/DNA 4.55 ± 0.78 4.20 ± 1.44 4.45 ± 1.80
Protein/DNA 22.2 ± 3.8b 18.4 ± 1.6a 24.0 ± 3.2b
Protein/RNA 5.30 ± 0.64 4.55 ± 0.66 6.01 ± 1.92
Data are means ± SD, n = 6. Control = piglets fed the basal diet and received
intrarectal administration of sterile saline; AA = piglets fed the basal diet and
administered intrarectally with acetic acid; NAC = piglets fed the basal diet
supplemented with 500 mg/kg NAC and received intrarectal administration of
acetic acid. a-b: Values within a row with different letters differ (P < 0.05).of EGFR mRNA (P < 0.05) compared to the control group.
Piglets in the NAC group have much higher levels of AR
mRNA (P < 0.05) than the other two groups. Also, colonic
mucosal TNF-α mRNA levels were lower (P < 0.05) in the
AA-treated piglets than in the control group and did not
differ from that in the NAC group. TLR4 mRNA abun-
dance did not differ among the three groups of pigs.
Discussion
The ulcerative colitis (UC) is a chronic inflammatory bowel
disease with mucosal inflammation and ulceration of the
colon [10]. In our study, dietary NAC supplementation
could decrease gross mucosal injury caused by AAIL-6, pg/mL 106.4 ± 23.6 115.2 ± 34.2 113.6 ± 18.3
PGE2, pg/mL 57.9 ± 11.5 55.1 ± 13.1 51.9 ± 11.8
EGF, ng/mL 0.65 ± 0.08ab 0.60 ± 0.07a 0.76 ± 0.10b
Colonic mucosa
IL-6, pg/mL 134.3 ± 12.7 133.6 ± 17.2 130.8 ± 11.3
PGE2, pg/mL 74.5 ± 3.9
a 96.0 ± 14.5b 90.5 ± 15.0b
TGF-α, pg/mL 3.50 ± 0.83a 4.28 ± 0.33b 2.56 ± 0.54c
Data are means ± SD, n = 6. Control = piglets fed the basal diet and received
intrarectal administration of sterile saline; AA= piglets fed the basal diet and
received intrarectal administration of acetic acid; NAC =piglets fed the basal diet
supplemented with 500 mg/kg NAC and received intrarectal administration of
acetic acid. a, b, c Values within a row with different letters differ (P < 0.05).
TNF-α tumor necrosis factor-alpha, IL-6 interleukin 6, PGE2 prostaglandin E2,
EGF epidermal growth factor, TGF-α transforming growth factor-α.
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Figure 1 Relative levels of caspase-3 expressed in the colonic
mucosa of piglets. Mucosal extracts (39 μg protein/sample) were
separated by 10% SDS-polyacrylamide gel electrophoresis for
determination of caspase-3 and β-actin. Values for relative caspase-3
abundance were normalized for β-actin. Data are means ± SD, n = 6.
Control = piglets fed the basal diet and received intrarectal
administration of sterile saline;
AA = piglets fed the same control diet and received intrarectal
administration of AA; NAC (AA + 500 mg/kg NAC) = piglets fed the
basal diet supplemented with 500 mg/kg NAC and received
intrarectal administration of AA. a, b Within the same intestinal
segment, means with different superscripts differ (P < 0.05).
Table 7 Effects of NAC on EGFR, AR, TNF-α and TLR4
mRNA levels in the colonic mucosa
Items Control AA NAC
EGFR 1.00 ± 0.29b 0.82 ± 0.19ab 0.61 ± 0.12a
AR 1.00 ± 0.17a 1.28 ± 0.20a 1.58 ± 0.17b
TNF-α 1.00 ± 0.16b 0.61 ± 0.16a 0.60 ± 0.11a
TLR4 1.00 ± 0.04 0.86 ± 0.34 0.71 ± 0.10
Data are means ± SD, n = 6. Control = piglets fed the basal diet and received
intrarectal administration of sterile saline; AA = piglets fed the basal diet and
received intrarectal administration of acetic acid; NAC = piglets fed the basal
diet supplemented with 500 mg/kg NAC and received intrarectal
administration of acetic acid. a-b: Values within a row with different letters
differ (P < 0.05). EGFR = epidermal growth factor receptor; AR = amphiregulin;
TNF-α = tumor necrosis factor-alpha; TLR4 = toll-like receptor 4.
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http://www.biomedcentral.com/1471-230X/13/133administration. The histopathology score for the AA
group was significantly higher than that in the control
and NAC groups (Table 3). The histologic ulcers
showed necrosis in the colonic mucosa with submuco-
sal inflammation, with neutrophils and lymphocytes0.00
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Figure 2 Relative levels of claudin-1 expressed in the colonic
mucosa of piglets. Mucosal extracts (52 μg protein/sample) were
separated by 12% SDS-polyacrylamide gel electrophoresis for
determination of claudin-1 and β-actin. Values for relative claudin-1
abundance were normalized for β-actin. Data are means ± SD, n = 6.
Control = piglets fed the basal diet and received intrarectal
administration of sterile saline;
AA = piglets fed the same control diet and received intrarectal
administration of AA; NAC (AA + 500 mg/kg NAC) = piglets fed the
basal diet supplemented with 500 mg/kg NAC and received
intrarectal administration of AA. a, b Within the same intestinal
segment, means with different superscripts differ (P < 0.05).being the predominant infiltrating cells. Moreover, we
observed crypt abscesses, granulomatous inflammation
with fibrosis, and massive thickening of the sub-
mucosa. Therefore, it could be concluded that the
crypt of the colon in the AA group was elongated with
distortion, while exhibiting the loss of epithelial cells,
ulceration, lymphocyte infiltration, bowel wall thicken-
ing, and goblet cells depletion in the colon (Figure 3).
These findings indicated that the UC model of piglet
has been successfully developed in the present study.
Fuss et al. [47] and Cetinkaya et al. [11] observed simi-
lar symptoms of macroscopic or microscopic colitis.
Jensen et al. [48] also reported that colostrum in-
creased mucin production by goblet cells as a first-line
defense against bacterial attachment and invasion.
Based on the biochemical parameters measured in the
blood and colonic mucosa as well as data on growth
performance, the experimental colitis at Day 7 post AA
administration was relatively “mild”. In the present
study, the AA administration increased the plasma and
colon MPO activities by 1.26 and 1.34 times, respect-
ively, and the plasma TNF-α level by 1.38 times,
compared with the control group. In the rat model,
AA-induced colitis was accompanied by an increase in
MPO activity by 14.4 [11] or 5.36 times [49]. Similarly,
MPO activity in the dextran sodium sulfate (DSS)-in-
duced colitis model was 22 times [50] higher, and
TNF-α level in plasma was approximately 100 times
[51] higher than that for the control group. Because
tissues were collected at Day 7 post AA administration
in the present study (Figure 4), the period of 7 days
was longer than that in other studies (e.g., 2 days or 5
days post administration of AA) [11,49], and we might
have missed the time when stronger colitis occurred.
In addition, to exclude a possible effect of AA-induced
reduction in food intake on the piglet intestine, the
control and NAC piglets were pair-fed the same
amount of feed per kg body weight as AA piglets dur-
ing days 15–21 of the trial (post-challenge with AA),
which may eliminate an anorexic effect of AA
Figure 3 Morphological change in the colon after intraluminal administration of acetic acid (AA). a: control group; b: AA group, colon
injury characterized by distortion of normal crypt architecture, loss of goblet cells, denuded epithelium, and infiltrating lymphocyte; c: NAC group,
histological changes were significantly improved by NAC treatment. A: goblet cells; B: denuded epithelium; C: lymphocyte
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dietary supplementation with NAC increased the num-
bers of goblet cells and cell density, while decreaseing
IEL and lymphocytic density. Furthermore, NAC
prevented the AA-induced decrease in the protein/
DNA ratio in the colon, which has been employed as
an indicator of intestinal growth and development
[52-54]. These results indicate that NAC could main-
tain the normal morphology of the colon and benefi-
cially alleviate the AA-induced damage.
Emerging evidence suggests that members of the
claudin-family of proteins play a critical role in tight
junction formation and also affect the permeability
characteristics in the gut [55]. Although the contribution
of other tight junction proteins is less clear, up-regulation
of claudin-1 appears to be a common mechanism by whichD 0D -7
7-day adaptation
Rectal pe
21-day feeding ex
Figure 4 The scheme of experimental design. After a 7-day period of ad
three groups: control group, AA group, and NAC group. On day 15 of the
administration of 10 mL of 10% AA, whereas piglets in the control group r
samples and colonic mucosae were collected.colonic epithelial barrier function can be maintained
and/or enhanced [56]. To extend these observations, we
analyzed the relative level of claudin-1 expression in the
colon mucosa. The results (Figure 2) showed that the
abundance of claudin-1 protein in AA-induced piglets
was decreased, when compared with the control group.
Notably, dietary supplementation with NAC substan-
tially increased the levels of claudin-1 in the colon mu-
cosa, indicating that NAC may improve the colonic
epithelial barrier function and alleviate the AA-induced
mucosal damage in young pigs.
Ulcerative colitis is a chronic recurrent inflammatory
bowel disease in which oxidative stress and cellular in-
jury have been implicated [11,57]. This is consistent with
elevated levels of TNF-α in the colonic mucosa of AA-
treated piglets (Table 7). NAC appears to act primarilyD 21D 15 D 22
rfusion with AA or saline
periment Colonic mucosa collection
aptation, eighteen piglets were assigned randomly into one of the
trial, piglets in the AA and NAC groups received intrarectal
eceived the same volume of sterile saline. On day 22 of the trial, blood
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imizing oxidative stress and the downstream negative ef-
fects of the stress [59]. MPO is an enzyme found
predominantly in neutrophils and has been used as an
effective quantitative index of inflammation due to a
positive correlation between MPO activities and neutro-
phil infiltration in the colon [11,60]. MDA is an import-
ant indicator to reflect the extent of ROS accumulation
in the body in response to oxidative damage [32]. Toxic
colitic injury has been shown to increase MDA levels in
rats [61,62]. Consistent with this report, we found that
NAC supplementation decreased MPO in the plasma as
well as MDA and TNF-α concentrations in the colon.
These findings suggest that NAC could alleviate AA-
induced oxidative injury in the colonic mucosa of piglets
and may have positive effects on reducing the severity of
colonic inflammation.
Oxidative stress and resultant tissue damage are the
hallmark of cell death. Of particular note, NAC attenu-
ated the production of active caspase-3 in the colon of
AA-induced pigs (Figure 1). Apoptosis is typically ac-
companied by the activation of a class of "death" prote-
ases (caspases) [63]. Caspase-3 stands out among the
known caspases, because it is commonly activated by
numerous "death" signals and cleaves a variety of import-
ant cellular proteins [64]. Thus, this protein is either
partially or totally responsible for the proteolytic cleav-
age of many proteins. Our results demonstrated that
NAC could effectively inhibit AA-induced apoptosis and
promote cell growth and survival, indicating a protective
effect of NAC against AA-induced colonocyte death
through inhibiting the activation of caspase-3. These
findings support the notion that NAC is effective in
preventing intestinal oxidative injury and inflammatory
disease in neonates [2].
Another novel and important observation of this study
is an increase in EGF concentration in the plasma of
NAC-supplemented pigs (Table 6). EGF can promote
proliferation, repair, and migration of epithelial cells in
the small intestine during the process of regeneration
after its damage [30,65]. EGF can accelerate gastric
ulcer healing by reducing bacterial colonization of the
ulcer [66]. Epithelial mRNA levels for EGFR appears
to be reduced or unchanged in patients with IBD [67].
In our porcine model of colitis, EGFR expression in
the colon mucosa was not affected. Moreover, AR (a
heparin-regulated growth factor) is a bifunctional
growth modulator: it interacts with the EGF/TGF-α re-
ceptor to promote the growth of normal epithelial cells
and inhibits the growth of certain aggressive carcinoma
cell lines [68]. The AR's mRNA level is markedly ele-
vated in the colon of NAC-supplemented piglets. AR
could facilitate colonic injury recovery via its growth-
regulatory effect.Conclusion
A piglet model of ulcerative colitis was successfully de-
veloped by intrarectal administration of 10 mL of 10%
AA. This disorder was characterized by a deregulation of
the colonic mucosal immune system along with the
presence of architectural distortion and infiltration of
neutrophils and macrophages. Dietary supplementation
with 500 mg/kg NAC alleviated ulcerative colitic injury
in AA-induced piglets. The beneficial effects of NAC
were associated with the following changes: 1) alleviated
colonic injury (indicated by a reduction in the AA-
induced damage of the colonic structure), 2) reduced
oxidative stress (indicated by decreased activities of
MPO in the plasma, elevated levels of MDA in the
plasma and colon), 3) reduced cell apoptosis (indicated
by decreased expression of the caspase-3 protein in the
colonic mucosa of AA-induced piglets), 4) enhanced re-
covery of the injured colon (increases in plasma EGF
concentrations and colonic mucosal AR mRNA levels),
and 5) enhanced formation of the tight junction (indi-
cated by increased expression of claudin-1 proteins in
the colonic mucosa of AA-induced piglets). Because AA
produces colonic inflammation in rodents that resembles
many histological characteristics of human ulcerative
colitis [16], and because intestinal physiology and physio-
pathology are very similar between pigs and humans [69],
our study helps to identify a beneficial role for dietary
NAC supplementation as an adjuvant therapy for ulcera-
tive colitis. Thus, findings from the porcine model may
have important implications for the treatment of human
intestinal disease (Crohn’s and ulcerative colitis).Abbreviations
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